内部成本效果审查结果：在不确定中看到希望。
The ICER review is in: hope amidst uncertainty.
机构信息
National Eczema Association, Novato, CA.
出版信息
J Manag Care Spec Pharm. 2022 Jan;28(1):115-118. doi: 10.18553/jmcp.2022.28.1.115.
Abstract
No funding contributed to the writing of this commentary. Smith Begolka, Butler, and Guadalupe are salaried employees of the National Eczema Association, which has received grants and sponsorship awards from a variety of industry partners, including AbbVie, Eli Lilly, Incyte, LEO Pharma, Pfizer, Regeneron, and Sanofi. Smith Begolka has received grant funding from Pfizer and advisory board honoraria from Pfizer and Incyte. Butler and Guadalupe have received advisory board honoraria from Incyte.
摘要
本文评论撰写未接受任何资金赞助。Smith Begolka、Butler 和 Guadalupe 是国家湿疹协会的受薪雇员，该协会从各种行业合作伙伴（包括 AbbVie、Eli Lilly、Incyte、LEO Pharma、辉瑞、Regeneron 和赛诺菲）获得了赠款和赞助奖励。Smith Begolka 获得了辉瑞的赠款资金，以及辉瑞和 Incyte 的咨询委员会酬金。Butler 和 Guadalupe 获得了 Incyte 的咨询委员会酬金。
相似文献
1
The ICER review is in: hope amidst uncertainty.
J Manag Care Spec Pharm. 2022 Jan;28(1):115-118. doi: 10.18553/jmcp.2022.28.1.115.
2
JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value.
J Manag Care Spec Pharm. 2022 Jan;28(1):108-114. doi: 10.18553/jmcp.2022.28.1.108.
3
Overview of alopecia areata for managed care and payer stakeholders in the United States.
J Manag Care Spec Pharm. 2023 Jul;29(7):848-856. doi: 10.18553/jmcp.2023.22371. Epub 2023 May 23.
4
Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition.
Br J Psychiatry. 2019 Jan;214(1):27-35. doi: 10.1192/bjp.2018.257. Epub 2018 Dec 6.
5
LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer.
J Urol. 2023 Jul;210(1):224-226. doi: 10.1097/JU.0000000000003518. Epub 2023 May 2.
6
The effectiveness and value of targeted immune modulators for moderate to severe ulcerative colitis.
J Manag Care Spec Pharm. 2021 Mar;27(3):405-410. doi: 10.18553/jmcp.2021.27.3.405.
7
Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pretreated relapsed and refractory multiple myeloma.
J Manag Care Spec Pharm. 2021 Sep;27(9):1315-1320. doi: 10.18553/jmcp.2021.27.9.1315.
8
Economic Evaluation of Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Cost-Utility Analysis.
J Drugs Dermatol. 2018 Jul 1;17(7):750-756.
9
The effectiveness and value of emicizumab and valoctocogene roxaparvovec for the management of hemophilia A without inhibitors.
J Manag Care Spec Pharm. 2021 May;27(5):667-673. doi: 10.18553/jmcp.2021.27.5.667.
10
Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial.
Br J Psychiatry. 2019 Feb;214(2):63-73. doi: 10.1192/bjp.2018.167. Epub 2018 Sep 25.
本文引用的文献
1
Financial burden and impact of atopic dermatitis out-of-pocket healthcare expenses among black individuals in the United States.
Arch Dermatol Res. 2022 Oct;314(8):739-747. doi: 10.1007/s00403-021-02282-3. Epub 2021 Sep 27.
2
Impact and Associations of Atopic Dermatitis Out-of-Pocket Health Care Expenses in the United States.
Dermatitis. 2022;33(6S):S43-S51. doi: 10.1097/DER.0000000000000795. Epub 2021 Oct 18.
3
Novel treatments for pediatric atopic dermatitis.
Curr Opin Pediatr. 2021 Aug 1;33(4):392-401. doi: 10.1097/MOP.0000000000001027.
4
Prior authorizations in dermatology and impact on patient care: An updated survey of US dermatology providers and staff by the American Academy of Dermatology.
Dermatol Online J. 2021 Jan 15;27(1):13030/qt990631n9.
5
Financial Burden of Atopic Dermatitis Out-of-Pocket Health Care Expenses in the United States.
Dermatitis. 2021 Oct 1;32(1S):S62-S70. doi: 10.1097/DER.0000000000000715.
6
Impact of prior authorizations on dermatology patients: A cross-sectional analysis.
J Am Acad Dermatol. 2021 Jul;85(1):217-220. doi: 10.1016/j.jaad.2020.07.095. Epub 2020 Jul 29.
7
Health care regulation, the Food and Drug Administration (FDA), and access to medicine: Our experience with dupilumab for children.
J Am Acad Dermatol. 2020 Jun;82(6):1568-1569. doi: 10.1016/j.jaad.2020.01.019. Epub 2020 Jan 17.
8
What's New in Atopic Dermatitis.
Dermatol Clin. 2019 Apr;37(2):205-213. doi: 10.1016/j.det.2018.12.007. Epub 2019 Feb 16.
9
Atopic dermatitis in US adults: Epidemiology, association with marital status, and atopy.
Ann Allergy Asthma Immunol. 2018 Nov;121(5):622-624. doi: 10.1016/j.anai.2018.07.019. Epub 2018 Jul 20.
10
Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study.
Ann Allergy Asthma Immunol. 2018 Sep;121(3):340-347. doi: 10.1016/j.anai.2018.07.006. Epub 2018 Jul 16.
Zotero 插件